Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2026
0mins
Source: Benzinga
- New Drug Approval: Bristol Myers Squibb's oral drug Sotyktu has received FDA approval for treating adults with active psoriatic arthritis, providing a new treatment option for alleviating joint and skin symptoms.
- Clinical Trial Results: In two global Phase 3 studies, 54% of patients taking Sotyktu achieved an ACR20 response by Week 16, compared to only 34% and 39% in the placebo groups, demonstrating significant treatment efficacy.
- Safety Profile: The drug's safety profile is similar to earlier psoriasis studies, with common side effects including respiratory infections and mouth ulcers; the FDA mandates tuberculosis screening before treatment to mitigate infection risks.
- Market Impact: This approval underscores Sotyktu's critical role in managing psoriatic arthritis, potentially enhancing Bristol Myers Squibb's position in the immunology market and driving further development in immune-related diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 56.440
Low
37.00
Averages
55.86
High
68.00
Current: 56.440
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roche's Divarasib Shows Positive Results in Late-Stage Study
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease year-over-year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery from a significant loss in the previous year despite facing pricing pressures and loss of market exclusivity risks.
- Growth Potential of Johnson & Johnson: Johnson & Johnson achieved approximately $94.2 billion in revenue for fiscal 2025, marking a nearly 6% year-over-year increase, with a net income of around $26.8 billion and a net margin of 28.5%, demonstrating the effectiveness of its dual strategy in innovative medicines and MedTech in driving financial growth.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6, indicating high reliance on borrowed funds, while Johnson & Johnson's ratio stands at only 0.6, reflecting a more robust financial structure, with current ratios of 1.3 and 1.0 respectively, highlighting differences in short-term debt coverage capabilities.
- Legal Risks and Market Competition: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, while Johnson & Johnson must contend with significant litigation risks related to its talc-containing products, which could impact financial results, and is at a disadvantage in the competitive landscape against biosimilars, illustrating the distinct challenges each company faces in their market environments.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease from the previous year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery after significant business shifts; in contrast, Johnson & Johnson achieved approximately $94.2 billion in revenue, up nearly 6% year-over-year, with a net income of $26.8 billion and a net margin of 28.5%, showcasing the strong growth potential of its diversified business model.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of about 2.6, indicating a high reliance on borrowed funds, with a current ratio of 1.3 suggesting adequate short-term debt coverage; in comparison, Johnson & Johnson's debt-to-equity ratio is only 0.6, with a current ratio of 1.0, reflecting its financial stability and lower debt risk.
- Market Competition and Risks: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, particularly regarding government-negotiated prices for key drugs like Eliquis, while the loss of exclusivity for Revlimid may open the market to cheaper generics; meanwhile, Johnson & Johnson must manage significant litigation risks related to its talc-containing products, which could impact financial results.
- Investment Value Assessment: Bristol Myers Squibb currently trades at a significant discount compared to Johnson & Johnson and the broader sector, and despite facing legal liabilities and market challenges, its
See More
Market Capitalization Comparison: Dell vs. Bristol Myers
- Market Cap Comparison: Dell Technologies (DELL) has a market capitalization of $134.70 billion compared to Bristol Myers Squibb (BMY) at $119.58 billion, indicating Dell's relative strength in attracting large fund investments.
- Investor Misconceptions: Many novice investors mistakenly believe that a higher stock price equates to greater company value, whereas market capitalization provides a more accurate comparison of company worth, aiding in informed investment decisions.
- Market Positioning Impact: Market cap determines a company's size tier among peers, directly influencing which mutual funds and ETFs are willing to hold the stock, particularly large-cap funds that prefer companies valued over $10 billion.
- Stock Performance: As of Tuesday's close, Dell's stock rose approximately 4%, while BMY remained flat, reflecting positive market sentiment and increased investor confidence in Dell.
See More
Analysis of the Importance of Market Capitalization
- Definition of Market Capitalization: Market capitalization is a crucial data point for investors as it provides a true comparison of the value attributed by the stock market to a company's stock, preventing beginners from misjudging a company's worth based on stock price alone.
- Company Valuation Comparison: Bristol Myers Squibb Co. (BMY) has a market cap of $119.58 billion, while Starbucks Corp. (SBUX) stands at $14.54 billion, highlighting a significant disparity in their market standings.
- Impact on Investor Decisions: Market capitalization determines a company's size tier among peers, influencing mutual funds and ETFs' investment choices, particularly as large-cap funds tend to favor companies valued over $10 billion.
- Market Performance Observation: At Tuesday's closing bell, BMY's stock fell approximately 1.5%, while SBUX remained flat, reflecting differing investor sentiments towards the two companies.
See More
US House Committee Investigates Pharma Trials at Chinese Military Sites
- Investigation Launched: The US House Select Committee on China has initiated investigations into Bristol Myers Squibb, Merck, Pfizer, and AbbVie regarding their clinical trials at Chinese military hospitals, highlighting significant concerns over their operations in sensitive regions, which could impact their business reputation in China.
- Pfizer's Positive Response: Pfizer CEO Albert Bourla announced that the company will cease trials in Xinjiang and at Chinese military hospitals, a decision that not only reflects a commitment to human rights but may also improve Pfizer's partnerships with Chinese biotech firms, enhancing its market image.
- Allegations Against Bristol Myers Squibb: Committee Chairman John Moolenaar's letter to Bristol's CEO Chris Boerner indicated that the company's trials in Xinjiang are linked to the CCP's genocide against Uyghurs and other minorities, potentially leading to legal and reputational risks for the firm.
- Future Impact Assessment: The committee seeks to understand Pfizer's due diligence processes and their implications for partnerships with Chinese biotech companies, information that will have far-reaching effects on the operational strategies of other pharmaceutical firms in China, particularly regarding compliance and ethical considerations.
See More
Roche's Divarasib Shows Positive Results in Late-Stage Study
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease year-over-year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery from a significant loss in the previous year despite facing pricing pressures and loss of market exclusivity risks.
- Growth Potential of Johnson & Johnson: Johnson & Johnson achieved approximately $94.2 billion in revenue for fiscal 2025, marking a nearly 6% year-over-year increase, with a net income of around $26.8 billion and a net margin of 28.5%, demonstrating the effectiveness of its dual strategy in innovative medicines and MedTech in driving financial growth.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6, indicating high reliance on borrowed funds, while Johnson & Johnson's ratio stands at only 0.6, reflecting a more robust financial structure, with current ratios of 1.3 and 1.0 respectively, highlighting differences in short-term debt coverage capabilities.
- Legal Risks and Market Competition: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, while Johnson & Johnson must contend with significant litigation risks related to its talc-containing products, which could impact financial results, and is at a disadvantage in the competitive landscape against biosimilars, illustrating the distinct challenges each company faces in their market environments.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease from the previous year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery after significant business shifts; in contrast, Johnson & Johnson achieved approximately $94.2 billion in revenue, up nearly 6% year-over-year, with a net income of $26.8 billion and a net margin of 28.5%, showcasing the strong growth potential of its diversified business model.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of about 2.6, indicating a high reliance on borrowed funds, with a current ratio of 1.3 suggesting adequate short-term debt coverage; in comparison, Johnson & Johnson's debt-to-equity ratio is only 0.6, with a current ratio of 1.0, reflecting its financial stability and lower debt risk.
- Market Competition and Risks: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, particularly regarding government-negotiated prices for key drugs like Eliquis, while the loss of exclusivity for Revlimid may open the market to cheaper generics; meanwhile, Johnson & Johnson must manage significant litigation risks related to its talc-containing products, which could impact financial results.
- Investment Value Assessment: Bristol Myers Squibb currently trades at a significant discount compared to Johnson & Johnson and the broader sector, and despite facing legal liabilities and market challenges, its
See More
Market Capitalization Comparison: Dell vs. Bristol Myers
- Market Cap Comparison: Dell Technologies (DELL) has a market capitalization of $134.70 billion compared to Bristol Myers Squibb (BMY) at $119.58 billion, indicating Dell's relative strength in attracting large fund investments.
- Investor Misconceptions: Many novice investors mistakenly believe that a higher stock price equates to greater company value, whereas market capitalization provides a more accurate comparison of company worth, aiding in informed investment decisions.
- Market Positioning Impact: Market cap determines a company's size tier among peers, directly influencing which mutual funds and ETFs are willing to hold the stock, particularly large-cap funds that prefer companies valued over $10 billion.
- Stock Performance: As of Tuesday's close, Dell's stock rose approximately 4%, while BMY remained flat, reflecting positive market sentiment and increased investor confidence in Dell.
See More
Analysis of the Importance of Market Capitalization
- Definition of Market Capitalization: Market capitalization is a crucial data point for investors as it provides a true comparison of the value attributed by the stock market to a company's stock, preventing beginners from misjudging a company's worth based on stock price alone.
- Company Valuation Comparison: Bristol Myers Squibb Co. (BMY) has a market cap of $119.58 billion, while Starbucks Corp. (SBUX) stands at $14.54 billion, highlighting a significant disparity in their market standings.
- Impact on Investor Decisions: Market capitalization determines a company's size tier among peers, influencing mutual funds and ETFs' investment choices, particularly as large-cap funds tend to favor companies valued over $10 billion.
- Market Performance Observation: At Tuesday's closing bell, BMY's stock fell approximately 1.5%, while SBUX remained flat, reflecting differing investor sentiments towards the two companies.
See More
US House Committee Investigates Pharma Trials at Chinese Military Sites
- Investigation Launched: The US House Select Committee on China has initiated investigations into Bristol Myers Squibb, Merck, Pfizer, and AbbVie regarding their clinical trials at Chinese military hospitals, highlighting significant concerns over their operations in sensitive regions, which could impact their business reputation in China.
- Pfizer's Positive Response: Pfizer CEO Albert Bourla announced that the company will cease trials in Xinjiang and at Chinese military hospitals, a decision that not only reflects a commitment to human rights but may also improve Pfizer's partnerships with Chinese biotech firms, enhancing its market image.
- Allegations Against Bristol Myers Squibb: Committee Chairman John Moolenaar's letter to Bristol's CEO Chris Boerner indicated that the company's trials in Xinjiang are linked to the CCP's genocide against Uyghurs and other minorities, potentially leading to legal and reputational risks for the firm.
- Future Impact Assessment: The committee seeks to understand Pfizer's due diligence processes and their implications for partnerships with Chinese biotech companies, information that will have far-reaching effects on the operational strategies of other pharmaceutical firms in China, particularly regarding compliance and ethical considerations.
See More
